Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : INCY save search
Anju Software Unveils Strategies for Data-Driven Decision-Making in Clinical Research at SCOPE Orlando 2024
Published: 2024-02-08 (Crawled : 16:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.02%
H: 0.65%
C: 0.02%
software research
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.45%
H: 0.52%
C: -0.94%
incb5470 positive study
Global Vitiligo Treatment Market 2023 - 2028: Ongoing Research and Advocacy Drive Progress
Published: 2023-09-01 (Crawled : 00:20) - prnewswire.com
CLVLY | $9.75 31.84% 1.6K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
CLVLF | $8.9 53.4% 2K
|
Health Technology
| Email alert
Add to watchlist
treatment ongoing research global market
Leiomyosarcoma Pipeline Research Report 2023: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - Assessment by Product Type, Stage, RoA, and Molecule Type
Published: 2023-07-15 (Crawled : 04:20) - prnewswire.com
CLVS | $0.0812 -3.94%
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
CLVSQ | $0.015 -3.33% 890K
|
n/a
| Email alert
Add to watchlist
companies report pipeline research
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
Published: 2023-05-08 (Crawled : 13:20) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
research
Myelofibrosis Treatment Market to Reach $1.16 Billion, Globally, by 2031 at 4.0% CAGR: Allied Market Research
Published: 2023-02-06 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.88%
H: 1.17%
C: -2.24%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.64%
H: 0.24%
C: -0.17%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: 0.11%
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.0%
H: 6.58%
C: 4.53%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.37%
H: 0.4%
C: -0.49%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.9%
GLTO | $0.72 4.71% 77K
|
Health Technology
|
| O: -1.11%
H: 3.36%
C: 1.12%
treatment research market
Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research
Published: 2022-10-07 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 6.33%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.63%
H: 0.76%
C: -0.26%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.14%
H: 0.16%
C: -0.91%
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
|
| O: -1.93%
H: 0.53%
C: -5.94%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.72%
H: 0.38%
C: -1.04%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: -1.78%
H: 1.45%
C: -2.55%
melanoma research
Glioma Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight
Published: 2022-08-08 (Crawled : 16:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
research report trial
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
Published: 2022-07-05 (Crawled : 12:00) - biospace.com/
MC | $51.65 1.33% 0.0% 590K
|
Finance
|
| O: -1.66%
H: 4.72%
C: 4.72%
TYME | $0.3107 -8.21%
|
Health Technology
|
| O: 24.6%
H: 0.0%
C: 0.0%
SYRS | $4.54 -3.81% -3.96% 260K
|
Health Technology
|
| O: 3.46%
H: 1.15%
C: -7.59%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.44%
H: 2.71%
C: 2.66%
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment approval
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.3%
H: 0.85%
C: -2.08%
new drug treatment fda application ces drug
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
Published: 2021-11-01 (Crawled : 12:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
Published: 2021-10-28 (Crawled : 12:15) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.49%
H: 1.01%
C: 0.69%
europe application
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
Published: 2021-09-14 (Crawled : 14:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.7%
H: 0.1%
C: -0.99%
collaboration research therapeutics
Incyte Announces Health Canada Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -2.7%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 4.43%
H: 0.21%
C: -0.55%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.3%
H: 0.03%
C: -0.29%
canada approval treatment approval t-cell
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.84%
H: 0.14%
C: -0.95%
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 0.92%
C: -26.05%
cancer research
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
Published: 2021-03-30 (Crawled : 11:00) - globenewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.47%
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -2.54%
H: 5.2%
C: 3.12%
cancer research
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Published: 2021-01-21 (Crawled : 22:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.01%
C: -2.59%
treatment potential cell carcinoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.